# Shukui Qin

Source: https://onco.cc/people/qin-shukui/  
OnCo record `qin-shukui` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Shukui Qin has led most of the Chinese liver cancer trials of the past decade, including the ones that put camrelizumab plus rivoceranib and donafenib into first-line use.

## Summary

Principal investigator of CARES-310 (camrelizumab plus rivoceranib versus sorafenib, Lancet 2023), the donafenib versus sorafenib trial (Journal of Clinical Oncology 2021), apatinib in second-line HCC and many Chinese cohorts of global liver cancer trials; past president of the CSCO and author of its liver cancer guidelines. His trials reflect the hepatitis B-driven Chinese HCC population that differs from Western cohorts.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Also known as: Qin Shu-Kui; 秦叔逵
- Tags: china
- Role: Professor of Medical Oncology; Nanjing Tianyinshan Hospital, China Pharmaceutical University (formerly Jinling Hospital, Nanjing)
- Specialisms: Hepatocellular carcinoma; Gastrointestinal oncology; Clinical trials

## Sources

- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Qin%20S%5BAuthor%5D%20hepatocellular%20carcinoma%20Nanjing

## Connected records

- institutions: [Chinese Society of Clinical Oncology](https://onco.cc/institutions/csco/)
- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Camrelizumab + rivoceranib](https://onco.cc/drugs/camrelizumab-rivoceranib/), [Donafenib](https://onco.cc/drugs/donafenib/), [Rivoceranib (apatinib)](https://onco.cc/drugs/rivoceranib/)
- trials: [CARES-310](https://onco.cc/trials/cares-310/), [ZGDH3 (donafenib vs sorafenib)](https://onco.cc/trials/zgdh3/)

---
JSON: https://onco.cc/api/v1/entities/qin-shukui.json